Angiotensin II receptor blockade in diabetic nephropathy

American Journal of Hypertension

Volumn 15, Issue 5, 2002, Pages 468-471

  Ruddy, Michael C ^a,b  

^a University Medical Center at Princeton   (United States)

^b Princeton Hypertension Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG INFUSION; EDITORIAL; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0036251204     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(01)02320-2     Document Type: Editorial

References (23)

1. Annual data report: Atlas of end-stage renal disease in the United States: Incidence and prevalence of ESRD
2. Preserving renal function in adults with hypertension and diabetes: A consensus approach
3. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
4. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association
5. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy
6. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
7. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
8. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
9. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
10. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
11. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
12. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
13. Microalbuminuria reduction with valsartan
14. Renin and prorenin
15. Angiotensin actions in the kidney: Renewed insight into an old hormone
16. The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms
17. Pathways for angiotensin II generation to intact human tissue: Evidence from comparative pharmacologic interruption of the renin system
18. The renin-angiotensin system in the year 2000
19. The epidemiology of plasma renin
20. Essential hypertension: Renin and aldosterone, heart attack and stroke
21. Renin: A risk factor for cardiovascular disease?
22. Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension
23. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors